| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $127.0M | +39.7% |
| SG&A Expense | $31.9M | +35.9% |
| Operating Income | -$158.8M | -38.9% |
| Income Tax | $0 | — |
| Net Income | -$133.8M | -33.6% |
| EPS (Basic) | -$1.45 | +7.6% |
| EPS (Diluted) | -$1.45 | +7.6% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $41.7M | -51.6% |
| Current Assets | $475.5M | +45.4% |
| Total Assets | $486.8M | +43.2% |
| Current Liabilities | $23.9M | +42.3% |
| Total Liabilities | $27.6M | +30.2% |
| Stockholders' Equity | $459.2M | +44.0% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$109.0M | -18.6% |
| Capital Expenditures | $1.3M | -77.2% |
| Investing Cash Flow | -$184.7M | -279.5% |
| Financing Cash Flow | $249.3M | +368.8% |
| Free Cash Flow | -$110.3M | -12.9% |